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Understanding The Role of ARGLU1 In Interferon Signaling Activation  
In Breast Cancer 
Phuoc Nguyen, M.S. 
Advisory Professor: Wenbo Li, Ph.D. 
In the U.S., the highest number of new cancer cases belongs to breast cancer in women, 
and this cancer also bears the second-highest death rate in women. Despite significant 
progress in breast cancer treatment that has been made in the past several decades, 
innovative and efficient therapies are still needed to eradicate this deadly disease. Novel 
cancer immunotherapy with immune checkpoint blockade (ICB) could induce long-lasting 
responses and improve survival in hard-to-treat malignancies. Regrettably, only a fraction 
of breast cancer patients respond to this highly promising strategy. To improving ICB 
therapy in breast cancer treatment, IFN signaling induction is a potential approach. Our 
results demonstrated that depletion of several RNA-binding proteins, particularly a poorly 
known ARGLU1, triggered type I interferon signaling in breast cancer cells. This 
phenomenon was also seen in mouse breast cancer cells but was not seen in normal 
breast epithelial cells. Furthermore, my results suggested that the loss of ARGLU1 
induced accumulation of dsRNAs, which were recognized by dsRNA sensors such as 
RIG-I and MDA5, leading to augmented IFN signaling. To identify RNAs directly bound 
by ARGLU1, Halotag-fused ARGLU1 was expressed in MCF7 cells for conducting CLIP-
seq. These results elucidate unappreciated regulators of type I IFN signaling in breast 
cancer, offering potentially new targets to overcome cancer resistance to immune 
checkpoint blockade therapy.   
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UNDERSTANDING THE ROLE OF ARGLU1 IN INTERFERON SIGNALING 
ACTIVATION IN BREAST CANCER 
CHAPTER 1: Introduction 
1.1 Breast cancer 
According to the American Cancer Society report in 2021, breast cancer accounts for 
30% of all new diagnoses and 15% of all estimated deaths, which are the highest number 
of new cases and the second-highest death rate in cancer for females [1]. 
 
Figure 1.1: The estimated new cancer cases and deaths for women in 10 cancer types, 
United States, 2021 [1]. 
The clinical treatment for breast cancer varies significantly between patients due to the 
highly heterogeneous property of this disease [2] [3]. Breast cancer can be sub-classified 
through molecular analysis by using gene expression profiling. The most critical genes 
are estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth 
factor receptor 2 (HER2). ER is a transcription factor and is located nuclear. Activated ER 
will bind to promoters and induces estrogen-dependent gene transcription. The ER-
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targeted genes participate in cell proliferation, inhibition of apoptosis, vasculogenesis, and 
proteolytic activity [4, 5]. ER activity is modulated by estrogen, a steroid hormone. 
Estradiol (E2), the most potent estrogen hormone, has an essential role in reproductive 
organs development, regulating the activity of the cardiovascular, musculoskeletal, 
immune, and central nervous system. E2 also makes a significant contribution to the 
initiation and development of cancer [6, 7]. HER2 is a receptor located on the cell 
membrane and has a role in signaling transduction to control cell proliferation and 
differentiation [8, 9]. Based on hormone receptors and HER2 expression, breast cancer 
could be divided into different biological subtypes. These are luminal A (positive with 
ER/PR, negative with HER2), luminal B (positive with ER/PR and HER2), HER2 
enrichment (negative with ER, PR, and HER2 overexpression), basal-like TNBC 
(negative with ER, PR, and HER2), and other particular subtypes [3] [10]. Following the 
sub-classification, breast cancer patients will be recommended for appropriate treatment 
strategies such as endocrine therapy, HER2 targeted therapy, and chemotherapy [11-
13]. Endocrine therapy is a core strategy for most patients who are positive with ER. This 
treatment involves using SERMs, SERDs, and AIs to interrupt the estrogen-dependent 
ER activity [14, 15].  
The first method, SERMs, works by competing with E2 to bind the ER. Among SERMS, 
Tamoxifen is the most well-known hormonal therapy. It binds to ER and blocks the 
attachment of E2 to the receptor. Consequently, the cell doesn't receive the estrogen' 
signal to grow and proliferate [16, 17]. Tamoxifen administration reduces the risk of 
relapse up to 50% during years 0-4 and continues for risk reduction of over 30% in years 
5-9 [18]. The second approach functions by reducing or eliminating ER expression using 
SERDs [19, 20]. Fulvestrant, for instance, works by binding to ER and reduces ER or 
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changes the shape of ER. The third approach operates by using the aromatase inhibitor 
to reduce estrogen and inhibit its production [21, 22]. After five years of treatment with 
SERM, following AIs treatment for 5 years adds a 40% relative risk reduction in relapse [4, 
18].  
Despite the benefits of tamoxifen, about 40% of breast cancer patients receiving 
tamoxifen still relapsed and eventually died from cancer [23]. The mechanism of 
tamoxifen resistance could be due to the loss of ER, one of two main types of estrogen 
receptor, or function due to missense mutations in the ligand-binding domain in the ER 
protein structure [24, 25]. Mutant ER confers an estradiol-independent activity, which is 
unaffected by tamoxifen virtually [26] [27]. Tamoxifen resistance could also be attributed 
to the high expression of ER co-activators. AIB1, a co-activator of ER, enhances the 
estrogen agonist activity of tamoxifen [28]. Additionally, there is crosstalk between ER 
and other GFR pathways that could drive the drug resistance. The downstream 
components of the HER2 signaling pathway, MAPKs ERK1 and ERK2, phosphorylated 
ER to enhance the ER's sensitivity to ligand, eventually leading to ligand-independent 
activation [29] [30]. In addition, kinase-mediated growth factor signaling enhances the 
activity of co-activators to modulate ER activity indirectly [31]. Moreover, resistance 
eventually develops to AIs. The mechanisms of this resistance include the 
hypersensitivity of ER to the low level of estrogen, the increased expression of the 
receptor, and the contribution of associated signaling such as HER-2, EGFR, IGFR [32]. 
Among HER2-enriched treatments, the monoclonal antibody Trastuzumab is the most 
promising candidate. It targets the HER2 tyrosine kinase receptor [33]. Trastuzumab 
diminishes HER2-mediated signaling through the mitogen-activated protein kinase 
4 
 
(MAPK) and phosphatidylinositol 3-kinase (PI3K) cascades. As a result, the cyclin-
dependent kinase inhibitor p27kip1 was induced and promotes cell death [34]. The 
objective response rates for patients treated by trastuzumab monotherapy ranged from 
12% to 34% in 9 months [35, 36]. However, the rate of primary resistance is 66% to 88% 
in Trastuzumab treatment. The mechanism of Trastuzumab resistance involves the loss 
interaction between Trastuzumab and HER2. Increased expression of MUC4 binds and 
prevents HER2 from interacting with Trastuzumab. IGFR or PI3K signaling pathway also 
contributed to  Trastuzumab resistance by attenuating Trastuzumab's effect on cell 
growth in HER2-overexpressing breast cancer cells [33]. 
TNBC subtype is a complex, heterogeneous, and aggressive form of breast cancer that 
is most difficult to treat. Endocrine therapy and anti-HER2 receptor therapy can not be 
used for TNBC patients due to the lack of hormone receptors and HER2 receptor 
expression. Hence, chemotherapy is the core strategy for TNBC treatment. Among those 
receiving neoadjuvant chemotherapy, about 40% of patients show a complete 
pathological response [37]. Those, who did not achieve a complete response, suffer from 
early relapse, develop resistance, or die because of metastatic stage [38]. 
Chemoresistance results from various  mechanisms, including the upregulation of 
transporter-mediated drug efflux [39], the presence of cancer stem cells (CSCs) [40], the 
increase of TGF-β signaling, which stimulates EMT, proliferation, angiogenesis, 
metastatic spread, chemotherapy resistance [41], and the changed Notch signaling, 
which helps tumors escape from the immune system and maintains CSCs [14, 42, 43]  
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In general, despite the innovations in breast cancer treatment, about 30% of early-stage 
breast cancers patients will develop recurrent advanced or metastatic disease [44]. New 
and more effective therapeutic strategies are still needed to eradicate this deadly disease. 
1.2 Immune checkpoint blockade (ICB) 
In recent years, therapeutic options for cancer treatment have changed tremendously 
with the development of immunotherapy [45, 46]. Among various types of 
immunotherapies, immune checkpoint blockade (ICB) induces a long-lasting response 
and improves survival, even in advanced and refractory cancers such as renal cell 
carcinoma metastatic melanoma, Merkel cell carcinoma, advanced non-small-cell lung 
cancer, classic Hodgkin's lymphoma, head and neck cancer, bladder carcinoma [47-49] 
The discovery of checkpoint proteins, including cytotoxic T lymphocyte-associated protein 
4 (CTLA-4) on T cells, programmed death 1 (PD-1) on T cells, and programmed death-
ligand 1 (PD-L1) on tumor cells or immune cells, results in the development of antibodies 
to target them [50, 51]. FDA approved many antibodies used in ICB for several cancer 
types [52]. 
CTLA-4 expression competes with the co-stimulatory receptor CD28 for binding to CD80 
or CD86, then blocks T cell function. The interaction between PD-1 and its ligand drives 
T cells into exhaustion [53, 54]. Blocking immune checkpoints has led to extraordinary 
robust responses to anti-tumors [55]. These promising results drive the expansion of more 
new immune checkpoint blockade antibodies [52]. However, the response rates widely 
differ by tumor type. Instance, NK (natural killer) T cell lymphoma and Hodgkin's disease 




To predicting the ICB response in cancer treatment, effective biomarkers were developed 
through clinical observations. The PD-L1 expression level is the most common biomarker 
was used to evaluate the effect of ICB in clinical practice [57]. Patients with tumors with 
positive PD-L1 expression have shown a high response rate to ICB in several cancer 
types, including urothelial cancer, non-small-cell lung cancer (NSCLC), TNBC [58]. 
Multiple studies have shown that several other intrinsic features of cancer cells may serve 
as biomarkers of response to ICB. The tumor mutational burden (TMB), which was 
identified by next-generation sequencing (NGS) in tumor samples, is correlated to ICB 
response in multiple cancer types [59] [60]. Neoantigens, which resulted from high TMB 
in the coding sequence, expressed and recruited the immune system to recognize them. 
Tumors upregulated immune checkpoints to repress immune response. This upregulation 
leads to tumors susceptible to ICB. However, identifying the optimal TMB threshold for 
potential responders of different cancer types remains a challenge to researchers. Other 
biomarkers were considered, such as neoantigen loading [59], DNA repair machinery 
defects [61, 62], the aberrant expression of repetitive elements, including ERVs. These 
biomarkers trigger innate immune signaling and upregulation transcription of immune 
checkpoint genes [63]. Furthermore, MHC class I and II protein expression are also 
potential biomarkers to predict the ICB response [64, 65]. 
ICB therapy has been evaluated in breast cancer, particularly in TNBC, which has a high 
TMB and higher PD-L1 expressions compared to other breast cancer subtypes [66, 67]. 
There are, however, no FDA-approved ICB agents for hormone receptor-positive 
subtypes with a low PD-L1 expression and low TMB. ICB has been proven effective when 
coupled with the right chemotherapy in subsets of HR-positive tumors [68] [69]. However, 
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only a fraction of breast cancer patients (i.e., 4.8% in all breast cancer subtypes) respond 
to the ICB strategy [70]. 
Interestingly, tumor cell-intrinsic IFN signaling has evaluated the importance of anti-tumor 
with ICB experience [71]. The resistance to ICB resulted from the deficiencies in interferon 
signaling and antigen processing. For instance, the loss function of JAK1 or JAK2 
occasioned in a lack of response to interferon-gamma, which plays an essential role in 
antiproliferative cancer cells. Expression of MHC class I could be blocked by a truncating 
mutation at the beta-2-microglobulin encoding gene [72]. Furthermore, IFN signaling 
primarily regulates PD-L1 expression by activating STAT3 and IRF3 [73, 74]. Hence, 
improving the efficacy of ICB for breast cancer might be facilitated by combining these 
agents with IFN signaling in tumor cells through boosting innate immune activation.  
1.3 ARGLU1- a poorly studied RNA binding protein  
In cancer development, besides the abnormal transcriptional activities and signaling 
pathways, aberrant posttranscriptional gene expression also contributes to the initiation 
and evolution of cancer [75, 76]. RNA binding proteins (RBPs) are critical regulators for 
gene expression at the posttranscriptional level. RBPs can interact with RNAs and other 
proteins to form ribonucleoprotein complexes that regulate all steps of RNA biogenesis, 
including microRNA (miRNA) processing, stability, alternative splicing, polyadenylation, 
and translation [77, 78]. Although numerous RBPs have been uncovered to join in a wide 
range of biological processes, their relationship with RNAs has not been entirely 
understood [79]. Numerous studies suggest that the dysfunction of RBPs is correlated 
with diseases, including cancer progression [80-82]. In cancer cells, many unusually 
expressed RBPs trigger the target RNA expression related to cancer cell propagation, 
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angiogenesis, apoptosis, senescence, EMT/invasion/metastasis, avoiding immune 
surveillance [75, 76, 83, 84]. These suggest that RBPs are vital regulators for cancer 
development, and targeting them is a potential approach in cancer therapeutics.  
One potential mechanism to improving ICB therapy might be combining it with IFN 
signaling activation. Accordingly, several studies showed that RBPs targeting induced 
IFN signaling in cancer cells [85-87]. DDX3X, an RNA binding protein that takes part in 
RNA metabolism like transcription, alternate splicing, RNA transport, and translation 
initiation [88], has increased expression levels in breast cancer at both primary and 
metastatic stages. The higher the DDX3X expression is, the worse the survival rate [89, 
90].  The loss of DDX3X triggers intrinsic type 1 IFN production by accumulating double-
strand RNA (dsRNA)- enhanced antigen presentation on cancer cells, and boosts anti-
tumor immunity in a syngeneic breast tumor mouse model [85]. Especially, DDX3X 
interacts with ADAR1, an RNA editing enzyme, to prevent the buildup of cytoplasmic 
dsRNAs in cells [85]. Significantly, the loss of function of ADAR1 in tumor cells increases 
the response to ICB in tumors [91]. ADAR1 binds to endogenous dsRNAs and possesses 
A-to-I editing activity, thus preventing the abnormal innate immune activation initiated by 
recognizing dsRNA sensors to dsRNAs [92, 93]. Furthermore, RNA editing is elevated in 
tumors compared to normal tissues and suggested to drive tumorigenesis [94]. However, 
the loss of ADAR1 function, either in normal or cancer cells, leads to the upregulation of 
unedited endogenous dsRNAs detected by cytoplasmic dsRNA sensors [93].  
Besides RNA editing, abnormal splicing also results in the activation of innate immune 
signaling. SF3B1, an RNA binding protein, services as U2 snRNP’s component, which 
plays an essential role in branch site recognition and spliceosome formation [95]. Notably, 
9 
 
the expression of SF3B1 in tumor cells is elevated as compared to non-tumor nearby 
regions. Targeting SF3B1 by a small molecular spliceosome modulator induces robust 
innate immune signaling in breast cancer cells. The downstream mechanism of this result 
is the mis-splicing and the accumulation of mis-spliced mRNAs, which are the pool of 
endogenous dsRNAs [87, 96].  
Unexpectedly, when we studied the role of RNA regulation in breast cancer, one less 
studied RNA binding protein, Arginine and Glutamate-rich 1 (ARGLU1), triggered type I 
IFN signaling in specific breast cancer cells. ARGLU1 is a protein named by the character 
of its two domains. The N-terminus is rich in arginine amino acids, and the C-terminus is 
rich in glutamate amino acids. Arginine and serine (RS)-rich repeats located in nuclear 
localization sequence in the N-terminus. These repeats were found in proteins with a role 
in alternative splicing by joining spliceosome structure and splice site selection [97]. 
ARGLU1 amplification has been reported in breast cancer patients (cBioPortal). ARGLU1 
has been shown to interact with Mediator subunit 1 (MED1). Using ChIP-reChIP assay, 
the results showed that ARGLU1 interacts with MED1 directly and colocalizes with it on 
the estrogen receptor target gene promoters. This interaction regulates target gene 
transcription upon estrogen induction and contributes to breast cancer cell development 
[98]. The ARGLU1 depletion impaired breast cancer cell growth and colony formation. 
Another publication showed the arginine-rich N-terminal of ARGLU1 binds to splicing 
factors and RNAs. Loss of ARGLU1 leads to changes in alternative splicing of genes 




Figure 1.2: ARGLU1 domains schematic. RS: arginine-serine repeats, NLS: nuclear 
localization sequences [99] 
Finally, while the practical and specific strategy treatment for breast cancer patients may 
be approached by applying highly promising therapy - ICB, only a fraction of patients 
respond to this therapy due to the meager existence of predictors such as PD-L1, tumor 
mutational burden. Alternatively, innate immune signaling shows a crucial role in cancer 
defense, T cell activation, and regulating PD-L1 expression. Thus, innate immune 
signaling might be induced by targeting RBPs such as ARGLU1. However, the critical 
molecular basis underlying how RNA deregulation leads to innate immune activation and 
IFN signaling remains unresolved. We hypothesize that ARGLU1, an RNA guardian, 
prevents aberrant cell-intrinsic IFN activation in mammalian cancer cells. The knowledge 
learned here will pave the way for new strategies to enhance the therapeutic efficacy of 









CHAPTER 2: ARGLU1 depletion-mediated type I IFN signaling activation in breast 
cancer cells. 
2.1. Background 
Type I IFN signaling pathway has a vital role in defending against pathogen invasion to 
protect the host. This pathway regulates this response by introducing numerous 
interferon-stimulated genes (ISGs) [100, 101]. Among ISGs, ISG15 is induced to regulate 
host immunity and prevent viral replication strongly and rapidly. ISG15 mediates ISG15 
conjugation (ISGylation) to regulate protein degradation by competing with ubiquitin at 
binding sites on the protein [102, 103]. ISG15 also served as a cytokine that modulates 
NK cell proliferation and DC maturation [104, 105]. OAS2 is a member of the 2,5 
oligoadenylate synthetase (OAS) and belongs to IFN-induced antiviral signaling. 
Activated OAS proteins catalyze the polymerization of ATP into oligomers, results in the 
activation of RNase L, which cleaves mRNA from cellular and virus, leading to JNK 
activation, ribotoxic stress, and apoptosis [106].  
2.2. Materials and Methods: 
Cell culture 
For a regular breast cell model, MCF10A, a human mammary breast epithelial cell, is 
widely used in vitro. This cell line was immortalized, obtained from the kindly proliferative 
breast tissue, and was not expressed in estrogen receptors [107].To examine whether 
depletion ARGLU1- mediated IFN signaling activation is cancer specific, MCF10A cells 
were used as a control.  
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The MCF7 cell line was purchased from ATCC and cultured in 10% FBS DMEM. The 4T1 
cell line was cultured in RPMI supplemented 10% FBS. The MCF10A cell line was 
acquired from ATCC and cultivated in DMEM/F12 supplemented with 5% FBS, 10µg/ml 
Insulin, 20ng/ml EGF, 0.5mg/ml Hydrocortisone, 100ng/ml Cholera toxin.  
The transient transfection 
MCF-7 cells were transfected with 40nM siARGLU1, a mixture of two siRNAs, (Sigma, 
siRNA with ID: SASI_Hs02_00351093 and SASI_Hs02_00351094) using 
Lipofectamine™ RNAiMAX (Thermo Fisher Scientific, Cat#13778075) for 72 hrs. 4T1 
cells were transfected with 40nM siARGLU1 (Sigma, siRNA with ID: 
SASI_Mm02_00346762). The non-targeting siRNA (Sigma, Cat#SIC001-1NMOL) was 
used as a negative control.  
RNA extraction, cDNA synthesis, and quantitative PCR (qPCR) 
RNA was extracted by using Quick-RNA Miniprep kits (Zymo Research, Cat#R1055). 
SuperScript IV First-Strand Synthesis (Invitrogen, Cat#18091050) was used to 
synthesize cDNA from total RNA. Then, cDNA was used as a template for qPCR with 
SYBR Green Supermix reagent (Bio-rad, Cat# 1725274).  
Western blotting 
Cells were washed with cold PBS and lysed in 1xLaemmli Buffer (Bio-rad, Cat#1610737) 
following incubation at 95 degrees C for 10 min. Protein samples were loaded to SDS-
PAGE and run in SDS tris-glycine running buffer. Proteins were transferred to 0.45µm 
PVDF membrane (Bio-rad, Cat#11620177) using the wet transfer system. After blocking 
in 5% BSA in 0.1% TBS-T for 1 hr, the membrane was incubated with ARGLU1 primary 
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antibody (Abnova, Cat#H00055082-B01P), GAPDH primary antibody (Proteintech, 
Cat#60004-1-Ig) overnight at 4 degrees C. Before incubating with secondary antibody for 
1 hr at room temperature, the membrane was washed three times, 5 min/time using TBS-
T. The membrane was then incubated with ECL Substrate (Bio-Rad, 170- 5060) and 
imaging with Imaging System (Bio-Rad). 
RNA sequencing 
Total RNA (200ng) was used for making the library following Illumina's protocol (Ultra II 
directional RNA Library Prep kit, Cat#E7760L) and sequenced on the Illumina NextSeq 
550 instrument.  
RNAseq mapping 
After demultiplexing by bcl2fastq, raw reads with low quality were processed using 
Cutadapt following alignment with the remaining reads hg19 reference genome by STAR. 
All subsequent analyses' coordinates and gene annotations were based on the human 
reference genome builds and the corresponding UCSC RefSeq genes. 
Differentially expressed gene analysis, read count for each gene was calculated by 
feature count software, then normalized to RPKM. Genes with two-fold change in 
ARGLU1 knock-down relative to the control sample were identified as differentially 






GO term enrichment analysis 
The list of upregulated genes in ARGLU1 depleted MCF7 compared to the control were 
input to the Metascape website then selected the significant enrichment pathways related 
to biological processes with FDR <0.01. 
Correlation analysis between ARGLU1 expression and IFN signature from TCGA 
The gene list was obtained from "virus" and "interferon" GO terms of the biological 
pathway enhanced in upregulated genes in ARLGU1-depleted MCF7. The gene-wise z-
score was calculated for each cancer type. The sum of genes in the IFN signature gene 
list was used for IFN signature characterization [108]. Pearson correlation coefficient 
(cor.test) was conducted using R to assess the correlation between ARGLU1 expression 
and IFN signature, p-value < 0.01.  
2.3. Results and Discussion: Depletion of ARGLU1 mediated IFN signaling 
activation in specific cancer cells. 
To test the role of ARLGU1 in RNA regulation in breast cancer cells, we knock down 
ARGLU1 using siRNA in MCF7 cells. Subsequently, RNA samples from knock-down and 
negative control samples were used for RNA sequencing. Based on the RNA seq result, 
differential expression analysis was applied. The result showed that 575 genes increased 
expression and 373 genes decreased expression in ARGLU1 depleted MCF7 compared 
to the control (Figure 2.1 A). From upregulated differential expressed genes list, we used 
Gene Ontology analysis to determine these genes involved in which Biological 
Processes. As shown in Figure 2.1 B, the type I Interferon signaling pathway was 
significant enrichment in knock-down cells. To confirming the enriched terms results from 
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GO analysis, we used a different method that is Gene Set Enrichment Analysis (GSEA), 
to analyze upregulated DEGs list. The result was similar with GO analysis – the genes 
related to inteferons and virus responses are highly enriched in ARGLU1 knock-down 
cells as compared to the control. It suggests ARGLU1 suppressed IFN signaling in MCF7 
cells. 
Figure 2.1: Depletion ARGLU1 induced the upregulation of genes belonging to the type 
I interferon signaling pathway. (A) Differentially expressed genes (DEGs) in ARGLU1-
depleted MCF7 cells as compared to the control. Cells were transfected with siARGLU1 
for 72 hrs. Upregulated genes are red dots, and downregulated genes are blue dots. (B) 
Bar graph of enriched terms across the upregulated DEGs list, colored by p-values. Data 
was used with permission from Dr. Joo Huyng Lee and Dr.Chuangye Qi.  
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Subsequently, to evaluate whether IFN signaling activation is mediated by ARGLU1 
depletion in the human breast cancer cell, MCF7, is consistent in mouse breast cancer 
cells. We depleted ARGLU1 using siRNA in 4T1. The expression of ISGs is induced by 
IFN signaling was checked by qPCR [109]. Transient knock-down reduced the expression 
of ARGLU1 at both the protein and RNA levels by more than 50% in MCF7 and 4T1 
(Figure 2.2 A and B). The expression of genes belonging to ISGs such as ISG15 and 
OAS2 was elevated in ARGLU1 depleted MCF7 and 4T1 compared to the negative 
control, respectively (Figure 2.2 C and D).  
To further develop new therapeutic strategies targeting cancer cells without affecting 
normal cells, we checked whether ARGLU1 depletion triggers IFN signaling activation in 
non-cancer cells. The expression of ARGLU1 at both the RNA and protein levels 
decreased by more than 50% in MCF10A (Figure 2.2 A and B). ISGs expressions, such 
as ISG15 and OAS2, were not elevated in depleted MCF10A cells compared to the 
negative control (Figure 2.2 C and D).  These data suggest ARGLU1 depletion leads to 
elevated ISGs expression in specific cancer cells. However, ARGLU1 protein was only 
quantitatively reduced, but not completely depleted, in breast cancer cells after 72 hours 
of transfection using siRNAs. An independent depletion method is still needed to examine 
the acute role of ARGLU1 in gene regulation. This independent method, which differs 
from siRNA, will allow us to confirm the ARGLU1-depletion-mediated IFN signaling 




Figure 2.2: ARGLU1 depletion induced IFN-stimulated gene expression in specific breast 
cancer cells. (A) and (B) Knock-down efficiency of ARGLU1 was confirmed using Western 
blot and qPCR in MCF7, 4T1, MCF10A. Western blot of GAPDH is a loading control. (C) 
and (D) ISG15 and OAS2 expression, respectively, in MCF7, 4T1, MCF10A cells with or 
without ARLGU1 depletion. Two-tailed unpaired Student's t-test. 
To further understand the correlation between ARGLU1 expression and the IFN signature 
in clinical cancer samples. We analyzed TCGA data with 30 cancer types and performed 
Pearson correlation coefficient (cor.test) using R. ARGLU1 expression showed a negative 
correlation with IFN signature in a number of cancer types, including breast cancer. This 
result supports that ARGLU1 expression negative regulates IFN gene transcription in 
breast cancer. Thus, targeting ARGLU1 is not only triggering IFN signaling activation in 
breast cancer but also for other cancer types, which have a negative correlation between 





Figure 2.3: The correlation between ARGLU1 expression and IFN signature in cancer 










CHAPTER 3: Establishment of a rapid degron system in MCF7 for ARGLU1 
degradation 
3.1. Background 
The available methods such as siRNA depletion, loss-of-function mutation, inhibitors, and 
CRISPR Cas9 allow the study of protein function in cells [110-114]. The disadvantage of 
these methods is the persistent condition of constantly disrupting protein function, the 
limited availability plus specificity of inhibitor molecules, the off-target effects, and multi-
component complexity [115]. Inducible degradation methods such as degradation tag 
(dTAG) systems can overcome these limitations [116]. The dTAG system provides a 
linker that links FKBP12-F36V fused with protein of interest to ubiquitin ligase and then 
degrades target protein through the ubiquitin-proteasome system [116, 117]. 
The PITCh system is used to insert FKBP12-F36V into the target protein. This system 
creates double-strand breaks in the repair donor vector (PITCh vector) and the genomic 
locus by using the Cas9 enzyme; the sequence of repair donor is then inserted into the 
locus of the target gene by MMEJ [118].  
3.2. Materials and Methods 
Construction CRIS-PITCh gRNA vector 
The DNA sequence of the last exon of ARGLU1 was uploaded to the CRIPOR website to 
choose the locus-specific gRNA and pick primers for cloning. Lilab#19036 plasmid with 
full name is PITcHv2 2xgRNA, and Cas9 were cleaved by BbsI enzyme (NEB, 
Cat#R3539)  to assemble the gRNA coexpress it with Cas9. The PCR product of gRNA 
was made with Q5® High-Fidelity DNA Polymerase (NEB, Cat#M0515). 5′-forward oligo 
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(caccggtccttctcattaaaaaccc) and 3′-reverse oligo (aaacgggtttttaatgagaaggacc) are 
generic oligos. 
Constructions CRIS-PITCh donor vector 
The FKBP12-F36V  was amplified from pCRIS-PITChv2-dTAG-BSD (BRD4) plasmid 
(Adgene, #91795) by Q5® High-Fidelity DNA Polymerase (NEB, Cat#M0515). 5′-forward 
oligo (cgggatccgactacaaggacgacgatgacaagggagtgcaggtggaaaccat) and 3′-reverse oligo 
(ccatcgatggaaccaccttccagttttagaagctcca) are oligos to amplify FKBP12-F36V, which 
contained the restriction site for BamHIII and ClaI enzyme, respectively.  
Pichv2-Flag-mAID-mClover-BSD-ARGLU1-Ctag (Lilab #20155) served as a backbone 
and was cleaved at BamHIII and ClaI site to remove mAID tag and assemble FKBP12-
F36V tag. 
Transformation 
Transform the product of construction into competent cells: 2μl of the products was mixed 
to 20 μl of cells and incubate on ice for 30 min. The mixture was heat-shocked at 42 
degrees C for 30 sec following incubation on ice for 3 min. The transformed bacteria were 
plated onto an LB plate supplemented with 100 μg/ml ampicillin and incubate overnight 
at 37 degrees C. 
Testing the construction 
One day after transformation, PCR-colony was performed using 5′-forward oligo 
(caccgacgctctaaccgctcgcctc) and 3′-reverse oligo (gggcgtacttggcatatgat) for gRNA 
construction vector and 5′-forward oligo (ttgtgtcgcccttaattgtg) and 3′-reverse oligo 
(gtggtgcagatgaacttcag) for FKBP-V construction donor vector. PCR products were run on 
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1% agarose gel with ethidium bromide to confirm the amplicon. Positive clones were 
selected and cultured in 5 ml of LB medium supplemented with 100 μg/ml ampicillin 
overnight at 37 degrees C, shaking. The plasmid was extracted using ZR Plasmid kit 
(Zymo Research, Cat#D4016). Plasmid samples were sent to Genewiz to confirm by 




Figure 3.1: Strategy to generate endogenous knock-in cells. (A) gRNA position located 
before stop codon in AGRLU1 locus. Two homology arms were chosen based on gRNA 
position. (B) CRIS-PITCh (v2)–mediated gene knock-in in cells. The repair donor vector 






Solution A contains 1000ng of donor vector, and 800ng of gRNA vector plus 3µl of P3000 
reagent (Lipofectamine™ 3000 Transfection Reagent kit, Invitrogen, Cat# L3000150)  
and was mixed to 125µl Opti-MEM. Solution B contains 3µl of Lipofectamine 3000 reagent 
(Lipofectamine™ 3000 Transfection Reagent kit, Invitrogen, Cat# L3000150) and mixed 
to 125µl Opti-MEM. Two solutions were incubated at room temperature for 5 min. Then, 
solution A was mixed with solution B and incubate at room temperature for 20 min. In that 
time, 300,000 MCF7 cells were seed to 6-well plates. After 20 min of incubation, the 
mixture was added to cells to get the final volume of 1ml, following keep cells in a 
CO2 incubator. After 8 hrs of transfection, the medium was replaced with 10% FBS DMEM 
supplemented 7.5µM RS1 (Sigma, Cat#R9782-5MG) and following selection with 
10%FBS DMEM containing 10μg/ml of Blasticidin (GOLDBIO, Cat#B-800-100) after 24 
hrs daily for 7 days. 
Knock-in confirmation 
Blasticidin-selected cells and wild-type MCF, a negative control,  were collected for Flow 
cytometry, which Cell Cytometry and Sorting Core conducted at Baylor College of 
Medicine with Cell Sorters: AriaI(M901). Using Countess II (Life technology, 
Cat#A27977), sorted cells were counted and seed to 200mm dish with 5000 cells to get 
single-cell clones, then a single-cell clone was picked up and transferred to a 48-well plate 
for growing. Following with genotyping clonal cells, genome DNA from 5000 cells of each 
clone was obtained using 10µl of QuickExtrac Solution (Lucigen, Cat#QE09050) at 65 
degrees C for 6 min and 98 degrees C for 2 min, then add 90µl DEPC water to each 
sample to get the final lysed sample for the next step. To genomic PCR, the pair of oligos 
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named F1R2 with 5′-forward oligo (aggccgaagaacagttgaga) and 3′-reverse oligo 
(tcaacatgaagctaccatacaaag) was used as the negative control. The pair of oligos named 
F1R1 with 5′-forward oligo (aggccgaagaacagttgaga) and 3′-reverse oligo 
(aaggtgcgcccgtctcctgg) was used as the positive control. The reaction of genomic PCR 
includes 2.5µl lysed sample, 1µl of 10µM each primer, 4µl Q5 buffer(NEB, Cat#B9027S), 
0.5µl dNTP, 12µl DEPC water, 0.15µl Q5 Polymerase. The reaction was run following the 
program in Table 3.1. The products of PCR were run on 1% agarose gel with ethidium 
bromide to confirm the amplicon. 
Table 1: The genomic PCR program 
98 degree C 2 minutes  
98 degree C 30 seconds 5 cycles 
63 degree C 30 seconds  
98 degree C 10 seconds 30 cycles 
63 degree C 30 seconds  
72 degree C 2 minutes  
 
dTAG treatment was also applied to confirm knock-in cells. GFP-positive cells were 
treated with 500nM dTAG13 (Fisher, Cat#66-055) for 24 hours and confirmed by western 





3.3 Results and Discussion 
The GFP tag (mClover is a modified GFP) and blasticidin resistant gene were introduced 
right after the FKBP12-F36V tag in the donor vector to select the knock-in cells. After 
selecting with blasticidin and by additional Flow cytometry sorting, my results showed that 
5.3% of cells are positive with GFP as compared to almost none in wild-type MCF7 
(Figure 3.2). To check whether GFP-positive cells respond to dTAG treatment, they were 
incubated with 500nM dTAG13 for 24 hrs. dTAG13, a degrader targeting FKBP12-F36V 
fusion protein, binds to FKBP12-F36V tag and E3 ubiquitin ligase to facilitate the target 
protein by ubiquitin-proteasome system [116]. Compared to the DMSO treated cells, 
dTAG treatment degraded the endogenous ARGLU1-FKBP12-F36V-mClover protein 
(Figure 3.3). The western blot result suggests one endogenous allele of ARGLU1 was 
inserted into the degron tag. It might also mean we got the heterozygous knock-in cells 
because the expression of endogenous ARGLU1 still exists in positive GFP cells.  
However, in GFP-positive cells, the presence of the protein has a molecular weight bigger 
than endogenous ARGLU1 and smaller than endogenous ARGLU1- FKBP12-F36V -
mClover and was not affected by dTAG treatment. It suggests that one more allele exists 
in the cell, and the microhomology end joining did not fully insert the tag to the genomic 
locus. 
Each of the individual cell clones from the mixture of GFP-positive cells was analyzed by 
genotyping to check the insertion of tags to the ARGLU1 locus. Using the oligo pairs F1R2 
as a negative control, the PCR product size with 236bp will be detected in wild-type 
MCF7. The clones with numbers 25, 33, 48, 3, 5, 7, which have no signal or are less 
signal than others, are potential homozygous or heterozygous clones (Figure 3.4).   
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Subsequently, potential homozygous or heterozygous clones were tested with oligo pair 
F1R1 as a positive control. The PCR product size will be 291bp. Only clones with numbers 
3, 5, 7, 37, 39, 48 showed a positive band. Later, clones, which number are 3, 7, 37, 39, 
were treated with 500nM dTAG13 for 24 hrs to check the response to dTAG treatment. 
dTAG13-treated clones reduced the endogenous ARGLU1-FKBP12-F36V-mClover 
protein as compared to DMSO-treated cells.  
 
 
Figure 3.2: Fluorescence-activated cell sorting of blasticidin selected cells. mClover 




Figure 3.3: dTAG treatment in the mixture of sorted MCF7 cells. Sorted MCF7 cells were 
treated with DMSO or 500nM dTAG13 for 24 hrs. Wild-type MCF7 cells are negative 
control. Western blot of GAPDH is a loading control. The band at ~75kDa is the ARGLU1 
with endogenous tag by FKBP12-F36V and mClover at its C terminus. 
 
 
Figure 3.4: Genomic PCR from single clones with negative control oligo pair F1R2. Oligo 
F1 targets the upstream of the start codon of the last exon of ARGLU1; oligo R2 targets 




Figure 3.5: Genomic PCR from single clones with positive control oligo pair F1R1. Oligo 
F1 targets the upstream of the start codon of the last exon of ARGLU1; oligo R1 targets 
the DNA sequence of the FKBP12-F36V tag. 
 
Figure 3.6: dTAG treatment in single clone lines. The clones number 3, 7, 37, 39 were 
treated with DMSO or 500nM dTAG13 for 24 hrs. Wild-type MCF7 is a parental cell line. 
The red arrow points to the FKBP12-F36V tagged ARGLU1 protein. 
These results show we successfully conducted the degron knock-in procedure and got 
heterozygous knock-in cell clones. Still, more single cell clones are needed to identify a 
homozygous knock-in so that I can deplete ARGLU1 rapidly. Some technical issues might 
affect the knock-in efficiency. ARGLU1 gene locates on chromosome 13 and likely has 
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three copy numbers in MCF7 cells according to Catalogue of Somatic Mutations in 
Cancer database and karyotype result from Sapino research [119]. The extra gene copy 
than diploid cells might impact the effectiveness of the CRIS-PITCh system to ensure that 
all copies of the gene are edited [120, 121]. Another problem is the effect of the FKBP-V 
tag on the ARGLU1 function. During the development of the FKBP tag, the result showed 
that Yellow Fluorescent Protein (YFG) function was not altered when fusion with the 
FKBP tag [122]. However, it is unclear that if this tag protein affects the function of 
ARGLU1 in cells. For example, the tag protein and protein of interest (POI) orientation 
may change intrinsic protein structure or post-translational modifications, which in some 
cases were reported to potentially induce cell death [122, 123]. That might be a reason 
for not achieving homozygous knock-in cells. To knock-in, beside insertation to the C-
terminal of ARGLU1, tag protein could be inserted to the N- terminus of ARGLU1. It could 
be tested to get the homozygous knock-in cell clone. To check whether tag protein causes 
mis-location of ARGLU1, knock-in cell clone will be examined by fluorescence imaging 
as the tagging will introduc mClover to ARGLU1 to allow direct imaging. The IFN signaling 
activation also needs to be confirmed in the knock-in cell clone under rapid ARGLU1 
depletion after dTAG treatment.  
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CHAPTER 4: Establishment of HaloTag-ARGLU1 overexpressing MCF7 for 
identifying the set of RNAs bind to ARGLU1 by CLIP-Seq 
4.1. Background 
RBP binds to RNAs and orchestrates RNA processing and function. To studying the role 
of RBP, several methods were developed to identify the set of RNAs that RBP binds in 
cells during development stages, activities, or disease states [124, 125]. 
RNA immunoprecipitation (RIP) is an approach to purify interest RNA-protein complex 
using antibodies under native conditions or formaldehyde cross-linking [126] [127]. The 
isolation of the RNA-protein complex is done in a non-stringent condition, and this low 
stringency results in low specificity.  
Cross-linking and immunoprecipitation (CLIP) are comparable to RIP but have one more 
step: cross-linking using ultraviolet (UV) light [128]. UV cross-linking is irreversible and 
more specific. Only proteins and RNAs which are in very close vicinity will be linked with 
a covalent bond. This bond permits to apply the stringent conditions during purification 
for RNA-protein complexes [129].  
However, major limitations of CLIP methods are the RNA loss during gel electrophoresis 
(SDS-PAGE) or the specificity of antibodies [130]. An alternative method was approached 
to purify the RNA-protein complex in stringent conditions by leaving out gel steps [130]. 
The introduction of Halotag to the protein of interest will allow the purification of RNA-
protein complexes by magnetic Halo beads in stringent conditions and independent of 




4.2. Materials and Methods 
Construction Halotag fused ARGLU1 plasmid  
The ARGLU1 coding sequence  without stop codon was amplified from lenti-ef1a-
dCasRx-HA-ARGLU1_T2A_EGFP plasmid (Lilab #19002) with 5′-forward oligo 
(ggtcccacccgcagttcgagaagtctagaggccggtctcggagccg) and 3′-reverse oligo 
(gccctctccactgcctgtacgtctagtaggcgcgccatcctgggtttttaatgag′). The lenti-ef1a-Flag-Halo-
Tev-StrepII-T2A-BSD vector (Lilab #20166) was cleavaged at XbaI restriction site and 
used as a backbone. Gibson Assembly method was used to ligate DNA segments for 1 
hour at 50 degrees C.  
Lentivirus production 
HEK293T cells were transfected with three plasmids to make lentivirus. Solution A 
contains psPAX2 (Addgene, #12260), pMD2.G(Addgene, #12259), target lenti Halotag-
ARGLU1 plasmid 3ug, 1ug, 4ug respectively, and was mixed with 500µl Opti-MEM, and 
incubate 5 min at room temperature. Solution B contains 10ul lipofectamine 2000 reagent 
(Thermo Fisher, Cat#11668500), and was mixed with 500 µl Opti-MEM, and incubate for 
5 min at room temperature. Solution A was mixed with solution B and incubate for 20 min 
at room temperature. During that time, HEK293T cells were prepared in 100mm dishes. 
After 20 min of incubation, the mixture was added to cells to get the final volume which is 
6ml, and cells were incubated in a CO2 incubator overnight. After 15 hrs, the medium was 
replaced with 10% FBS DMEM and incubate cells for 24 hrs. Then, the medium containing 






1ml viral medium was added to MCF7 in a 6-well plate with 8 µg/ml polybrene (Sigma 
#H9268). After 24 hrs of incubation, cells were replaced with a medium containing 10 
µg/ml blasticidin for selection. Non-infected MCF7 cells are a negative control.  
Halo Protac treatment 
MCF7 stable line was treated with DMSO or 5µM Halo Protac (Promega, 
Cat#CS2072A01) for 6 hrs. 
CLIP 
MCF7 stable line was cross-linked using UVP crosslinker at 254 nm, 400mJ/cm2. Cross-
linked cells were then scraped off the plate and centrifuge to collect cell pellets. The 
pellets were lysed in Lysis Buffer supplemented with 0.5 mM CaCl2, 2.5 mM MnCl2, 1× 
protease inhibitor cocktail, 20U Turbo DNase, 200U Riboblock) and incubate for 10 mins 
on ice. The sample was incubated in Thermomixer at 700 rpm, 37 degrees C for 10 min, 
then centrifuge 15.000g, 4 degrees C for 15 min. The supernatant was transferred to a 
new tube, kept on ice. 5% of supernatant was set aside for input. The remainder of the 
supernatant was mixed with 200μl Magnetic Halo beads slurry (Promega, Cat#G7282) 
and rotate at 4 degrees C overnight. 5% of the unbound fraction was kept for checking 
the efficiency of the pull-down. Beads were washed three times at 90 degrees C for 3 min 
while shaking on Thermomixer at 1200 rpm with buffers: 1X NLS buffer, High salt buffer, 
8M Urea buffer, Tween buffer, and TEV buffer. ARGLU1–RNA complexes were split off 
the Halo beads by TEV protease (Sigma, Cat# T4455-10KU) at room temperature for 5 
hrs. Then RNA-protein complex, input, unbound samples were added 4xLDS buffer 
(Thermo Fisher, Cat#NP007) and 1M DTT at ratio 1:10 volume for western blot analyzing.  
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Table 2. The component of buffers used in CLIP [131] 
Buffer Components 
Lysis Buffer 50 mM HEPES, pH 7.4, 100 mM NaCl, 1% NP-40, 0.1% 
SDS, 0.5% Sodium Deoxycholate 
1X NLS Buffer 1xPBS, 2% NLS, 10 mM EDTA 
High Salt Buffer 50 mM HEPES pH 7.4, 0.1% NP-40, 1M NaCl 
Urea Wash Buffer 50 mM HEPES pH 7.5, 0.1% NP-40, 8M Urea 
5xPNK Buffer 350 mM Tris-HCl (pH 6.5), 50 mM MgCl2 
Tween Buffer 50 mM HEPES, pH 7.4, 0.1% Tween 20 
TEV Reaction Buffer 50 mM Hepes pH7.4, 1 mM EDTA, 0.1% NP40 
 
4.3 Results and Discussion 
The Halotag has modified haloalkane dehalogenase, which is created to bind to HaloTag 
ligands covalently. The chloroalkane linker forms a covalent bond with the protein tag in 
a precise manner. This bond occurs quickly and is stable even when heated at 95 degrees 
C. It is essentially irreversible, allowing this binding to avoid denaturing purification 
conditions. From that, gels steps in CLIP are not needed to purify cross-linked protein-
RNA complexes [132]. Furthermore, establishing a stable cell line that expresses Halotag 
fusion protein can be confirmed by using Protac. Protac is a small molecule that links 
Halotag-fused protein to E3 ligase to induce ubiquitination and protein degradation by the 
proteasome [133]. 
In MCF7 stable line, Halotag fused ARGLU1 protein was expressed compared to MCF7 
wild type. However, Halotag fused ARGLU1 protein was degraded upon 5µM Halo Protac 
treatment for 6 hours compared to DMSO treated stable cells (Figure 4.1 B). It means we 
successfully established a stable cell line that expresses Halotag-ARGLU1 to do CLIP. 
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The next step is to purify RNA-protein complexes without conducting gel steps in 
traditional CLIP methods. The DNA sequence for TEV protease was inserted into the 
middle of the Halo tag and ARGLU1 in the plasmid (Figure 4.1 A). TEV enzyme 
recognizes a seven-amino-acid consensus peptide substrate Glutamic acid/ Aspartic acid 
/Leucine/Tyrosine/Phenylalanine/Glutamine/Serine or Glycine (ENLYFQS/G) and, most 
importantly, is highly sequence-specific [134]. This design allows cleaving a protein-RNA 
complex off the Halo tag protein bound by magnetic Halo beads in purification steps. After 
pulling down by using Halo beads, the sample was treated with 10, 50, 100, or 200 units 
TEV for 5 hours at RT. Western blot analysis showed that most Halotag-ARGLU1 
complex in the unbound fraction was less than the input (Figure 4.2 A), suggesting that 
these protein complexes effectively bound to the beads. Compared to the input, the 
western blot result shows that ARGLU1 proteins were cleaved off the Halo beads using 
the TEV enzyme (Figure 4.2 B). The TEV-released ARGLU1 has a larger molecular size 
as compared to the endogenous ARGLU1 due to UV cross-linking. Under UV treatment, 
the covalent bond forms between RBP and RNAs, which RBP binds. Those events lead 








Figure 4.1: Halotag fused ARGLU1 expression under Protac treatment. (A) Halotag-
ARGLU1 protein diagram. (B) The expression level of Halotag-ARGLU1 in MCF7 stable 
cells compared to endogenous ARGLU1 with or without 5µM Halo Protac for 6 hours. 
Wild-type MCF7 cells are used as a control.  
After all, the stable cell line, Halotag-ARGLU1 overexpressing MCF7 cells, was 
successfully established upon checking with Halo Protac treatment and Western blot. 
Under TEV treatment, Halo beads-purified ARGLU1 was cleavaged off the Halo beads. 





Figure 4.2: The isolation of ARGLU1–RNA complexes using Halo beads. Western blot 
GAPDH as a loading control.  (A) Comparison of Halotag-ARGLU1 protein in Input vs. 













CHAPTER 5: Mechanism of depletion ARGLU1 mediated IFN signaling activation  
5.1. Background 
Type I interferon signaling activation relies on detecting pathogen-associated molecular 
patterns (PAMPs) to create an important defense against infection. PAMPs were found 
in bacteria, viruses, and parasites but were not seen in host cells. The immune system 
recognizes these patterns as "non-self," so the host was not destroyed through pattern 
recognition receptors (PRRs) activity [135, 136]. In case of virus infection, to distinguish 
nucleic acid between host and virus, two criteria were used by PRRs to recognize viral 
nucleic acids exclusively. The first criteria are based on a specific location within the cell, 
such as the cytoplasm and nucleus. For example, cGAS, a PRR, detects DNA in the 
cytosol and will presume that DNA has a viral origin because host DNA was assumed not 
to be found in uninfected cells' cytosol [137, 138]. 
The second criteria are based on the DNA/RNA characteristics [139] [135]. Unmethylated 
CpG DNA, which origins from bacterial or viruses, is a type of extraneous DNA. Toll-like 
receptor 9 (TLR9) binds to unmethylated CpG DNAs, which were mostly not found in host 
cells to trigger IFN signaling [140, 141]. Double-stranded RNAs (dsRNAs) are the best 
foreign features of RNA [142]. As a result of viral RNA replication, dsRNAs accumulated 
during viral infection. The discrimination between cellular dsRNA versus viral dsRNA was 
based on dsRNA sensors regulating innate immunity systems, such as RIG-I, MDA5 [143] 
[144]. RIG-I and MDA5 detect viral dsRNAs and activate MAVS, the downstream adaptor 
of signaling. The activation of MAVS recruits various signaling molecules such as TRAFs, 
TBK1, and IRF3/7, triggering the upregulation of type I interferons transcription and 
proinflammatory cytokines [145]. RIG-I recognizes dsRNA structure in a dependent on 5′-
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triphosphorylated ssRNA (longer than 23 nucleotides) as well as short dsRNA (less than 
300 nucleotides) [146, 147]. 5′triphosphorylate, which was seen in nascent RNAs, is 
discarded from RNAs via standard 5′ processing in the nucleus [148]. On the other hand, 
MDA5 recognizes dsRNA independent on 5′ triphosphorylate and requires long dsRNA 
(longer than 0.5 kb) [149, 150]. 
5.2. Materials and Methods 
Transient transfection 
For immunofluorescence staining, MCF7 cells were transiently transfected with 40nM 
siARGLU1 or siCTL for 72 hrs or 10mg Polyinosinic: polycytidylic acid (Sigma, Cat# 
P9582-5MG) for 24 hrs by using Lipofectamine™ RNAiMAX reagent. Cells were put on 
glass coverslips in a 24-well plate well. For double knock-down genes, MCF7 cells were 
transfected with 40nM siARGLU1 and 20nM siDDX58 (Sigma, siRNA 
ID:SASI_Hs01_00047980) or siIFIH1 (Sigma, siRNA ID:SASI_Hs01_00171929) using 
Lipofectamine™ RNAiMAX for 72 hrs.  
Fluorescent Immunohistochemistry 
Cells were washed with cold PBS and fixed with a 3.7% formaldehyde for 15 min at room 
temperature, followed washed three times with PBS, and permeabilized with PBS 
containing a 0.2% Triton X-100 for 30 min temperature. After blocking with 3% BSA in 
PBS  for 1 hr at room temperature, cells were incubated monoclonal anti-dsRNA J2 
(Scicons, Cat#10010500) overnight at 4 degrees C. Cells were incubated with secondary 
antibody (Alexa Flour 594 goat anti-mouse IgG (Invitrogen, Cat#A-11032)) for 1 hr at 
room temperature in the dark after washing three times with PBS. Later, cells were 
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washed three times with PBS and counterstained with 300nM DAPI in the dark at room 
temperature for 5 min. Cells were washed three times with PBS before inverting onto gel 
mount on microscope slides [151]. 
J2 immunofluorescence imaging and analysis 
Cells were imaged on a confocal with Z stacked (0.5m) setting under a 40X objective 
lens. ImageJ software was used to measure the fluorescent intensity for each cell and 
background defined in the same image. J2 immunofluorescent intensity of cell was 
identified by the difference intensity between the area of each cell and background. J2 
immunofluorescence intensity was normalized to the mean intensity of cells in the 
negative control sample [87]. 
Intron retention (IR) analysis 
Sequencing reads with the low quality were filtered out, the remaining mapped to hg19 
reference genome by using STAR with those parameters (--sjdbGTFfile --outSAMtype 
BAM SortedByCoordinate --outFilterMultimapNmax 20 --outFileNamePrefix ). Proper-
paired reads were kept for further analysis by Samtools. Intron coordinations were 
extracted according to gene annotation of Refseq. Read counts to introns were calculated 
by using Featurecount. Based on the intron feature, two read classes were defined. First, 
the "intronic" reads are the ones with greater than five bases contiguously within the 
intron. Second, the "spanning" reads are the ones with ends overlapped with the flanking 
exons. The “intron retention score” is defined by the ratio of the normalized "intronic" read 
density over the normalized "spanning" read density. To comparing differentially 
expressed intron retention events across samples, introns with low expression were 
excluded for the following analysis. Ggplot2 generated empirical cumulative distributions 
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of intron retention scores; meanwhile, p-values estimated using the Kolmogorov-Smirnov 
test [87]. 
5.3 Results and Discussion 
ARGLU1-depleted MCF7 cells triggered type I interferon and defense to response virus 
signaling (Figure 2.1). Some existing RNA features can induce IFN signaling activation, 
such as dsRNA, 5’ppp RNAs [145]. To test whether ARGLU1 knock-down leads to the 
accumulation of dsRNA. We performed J2 immunofluorescence in ARGLU1-depleted 
MCF7 cells and negative control cells. For dsRNA detection, monoclonal J2 antibody is 
a gold standard that specifically recognizes dsRNA with a greater length than or equal to 
40bp. This recognition is independent of the sequence and nucleotide composition of the 
antigen [152]. In the experiment using the J2 antibody, poly I:C treated cells are positive 
control. Poly I:C, Polyinosinic: polycytidylic acid, is a synthetic analog of dsRNA 
associated with viral infections and could be detected by J2 antibody [153]. Poly I:C-
treated MCF7 cells increased J2 signal compared with the control cells (Figure 5.1). That 
result indicating the J2 antibody recognized the dsRNA structure specifically. As shown 
in figure 5.1, the J2 signal increased in ARGLU1 depleted cells compared to control cells. 
It suggests ARGLU1 depletion upregulated dsRNAs in the cytosol.  
Previous studies have shown that the detection of cytoplasmic dsRNA triggered type I 
interferon signaling through dsRNA binding proteins, called dsRNA sensors [87, 108, 
154]. To test how dsRNA sensors recognize dsRNAs and induce IFN signaling activation 
in ARGLU1 depleted MCF7 cells, we depleted individual well-known dsRNA sensors, 
including RIG-I and MDA5 ARGLU1 using siRNA, and tested the expression of ISGs. 
Depletion of dsRNA sensors, either RIG-I or MDA5, suppressed the expression of 
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representative ISG genes such as ISG15 and OAS2 at RNA levels as compared to 
ARGLU1 knock-down cells (Figure 5.2). This result supports RIG-I and MDA5 as potential 
dsRNA sensors involved in IFN signaling activation in ARGLU1-depleted MCF7 cells. 
Together, these data support that upregulated dsRNAs were likely sensed by dsRNA 
sensors such as RIG-I, MDA5 upon the loss of ARGLU1 in MCF7 cells.   
 Figure 5.1: dsRNA accumulated in ARGLU1 depleted MCF7. (A) Immunofluorescence 
staining by dsRNA J2. Poly I:C treatment for 24 hrs is a positive control. (B) Quantification 
of cytoplasmic dsRNA immunofluorescence signal. In quantification plots of intrinsic-
dsRNA immunofluorescence signal, the intensity is mean ± SEM from 16 cells of each 
treatment, two-tailed unpaired Student's t-test. 
Then, we assess the source of upregulated intrinsic-dsRNA in ARGLU1-depleted cells. 
ARGLU1, an RNA binding protein, interacts with splicing factors to regulate the alternative 
splicing events. Abnormal splicing events induce defects in slicing, such as intron-
retention [155]. Introns are a large proportion of retrotransposable elements that can form 
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dsRNA structures in cells  [156]. Thus, we validate the intron-retention in knock-down 
cells compared to control based on RNA-seq results. We identified intronic reads within 
the intron and spanning reads in the intron and flanking with the exon. The ratio of intronic 
read density with spanning read density will give to the intron-retention score. As shown 
in Figure 5.3, the intron-retention score is not significantly different between the knock-
down and control samples. It suggests retained intron is not a source for upregulated 
dsRNAs due to the ARGLU1 depletion in MCF7 cells.  
Overall, these data provided information on how type I Interferon signaling was activated 
in ARGLU1-depleted MCF7. The upregulation of dsRNAs and the sensing of dsRNAs by 
dsRNA sensors, including RIG-I, MDA5 triggered the type I Interferon pathway. Moreover, 
ARGLU1 depletion did not lead to the retained intron, a source of dsRNAs.  Based on 
these results, we suggest that the ARGLU1 function did not involve the intron-retention, 
a splicosome perturbation.  
To better determine the source of dsRNAs, we will perform J2 immunoprecipitation 







Figure 5.2: dsRNA sensors contribute to the expression of ISGs in ARGLU1 depleted 
MCF7 cells. Two-tailed unpaired Student's t-test. 
 
 
Figure 5.3: Intron-retained RNAs did not change in response to ARGLU1 knock-down in 




CHAPTER 6: Overall summary and Discussion 
To improve the response of ICB therapy, targeting IFN signaling activation is a potential 
method to enhance the specificity and effectiveness in breast cancer treatment. Our 
results have shown that the depletion of RNA binding protein, ARGLU1, triggered type I 
interferon signaling activation in MCF7. Otherwise, interferon-stimulated genes such as 
ISG15, OAS2 did not increase their expression in MCF10A. Additionally, ARGLU1 
expression negatively regulates IFN gene expression in breast cancer types. 
A part of the mechanism underlying ARGLU1 depletion mediated IFN signaling activation 
was discovered in MCF7 cells in this study. The dsRNAs upregulation following the 
recognization of dsRNA sensors such as RIG-I and MDA5, activated type I Interferon 
pathway. Activation of type I Interferon pathway through dsRNA recognition has been 
explored in DNA methyltransferase [157], AGO1 perturbation [158], m6A modifications 
[159]. However, the source of dsRNAs is unclear in our scenarios.  
The successful establishment of Halotag-ARGLU1 overexpressing MCF7 cells is a 
valuable tool for CLIP-seq to identify RNAs that ARGLU1 bound. The finding of these 
RNAs will contribute to elucidate the function of ARGLU1 in regulating transcription. 
Furthermore, degron systems were developed and widely used to degrade target protein 
rapidly and reversibly to study protein function [116, 133, 160]. We established the 
heterozygous knock-in cell line, which allowed ARGLU1 degradation using small 
molecular dTAG13. The ability to respond to dTAG treatment is still needed to examine 
the different timelines in this cell line. Rapid ARGLU1 degradation will support the model 
that mimics the inflammation event, which will allow us to understand more about the 
mechanism of IFN signaling activation in cells. 
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In the upcoming, it is crucial to reveal pools of endogenous dsRNAs, RNAs that were 
bound by ARGLU1, and the function of RNA-ARGLU1 complexes in gene transcription at 
chromosome levels. The potential of inhibiting ARGLU1 to sensitize ICB therapy also 
needs to be investigated further in breast cancer models. First, proper animal models 
need to be selected to test the role of ARGLU1 knockdown on tumor immunity and 
immunotherapy. Indeed, different mouse breast cancer cell lines were recently found to 
be very distinct in their immune-subtypes and responses to immunotherapy [161], 
consisting of neutrophile and macrophage dominant subtypes. Second, besides the IFN 
signaling activation, some other factors are also important contributor to tumor response 
to ICB therapy. For example, the neoantigen processing and presentation in cancer cells, 
the infiltrating of lymphocytes such as T cells, B cell, NK cells, neutrophils, macrophages 
in the tumor are important variables  [161-163], which shall be considered for my future 
work. It is possible that I should test the in vitro tumor response to ARGLU1 knockdown 
in a series of mouse cell lines before focusing on two for in vivo work. I should more 
thoroughly test the tumor microenvironment and infiltrating leukocytes in these animal 
models to better understand how ARGLU1 may play roles in altering tumor immunity and 
ICB therapy. 
Overall, our findings reveal that ARGLU1 depletion-mediated IFN signaling activation 
beyond dsRNAs accumulation and sensing in breast cancer cells. We established two 
cell lines: Halotag-ARGLU1 overexpressing MCF7 cells and heterozygous knock-in 
MCF7 cells. They are powerful tools to study the biological function of ARGLU1 in 
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